AAG
IHE icon

Armstrong Advisory Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Armstrong Advisory Group’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-104
Closed -$19.3K – 812
2024
Q1 		$19.3K Sell
104
-208
-67% -$13.8K ﹤0.01% 487
2023
Q4 		$19.3K Hold
312
– – ﹤0.01% 487
2023
Q3 		$18.4K Hold
312
– – ﹤0.01% 509
2023
Q2 		$18.6K Hold
312
– – ﹤0.01% 505
2023
Q1 		$18.2K Hold
312
– – ﹤0.01% 492
2022
Q4 		$19.4K Buy
+312
New +$18.8K ﹤0.01% 496

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
RW
Rockport Wealth Fairview Park, Ohio $549M AUM 22.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Armstrong Advisory Group's IHE Position: Q2 2024 in Review

Armstrong Advisory Group sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2024, closing a stake of 104 shares — an estimated $19.3K sold.

Armstrong Advisory Group first reported a position in IHE in Q4 2022 and held it in 6 quarters. The position peaked at $19.4K in Q4 2022. 143 funds tracked by Wall St. Rank hold IHE as of Q2 2024.

  • Armstrong Advisory Group reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2024 after selling out during the quarter.
  • Armstrong Advisory Group sold 104 iShares US Pharmaceuticals ETF shares in Q2 2024, an estimated $19.3K.
  • Armstrong Advisory Group first reported a position in iShares US Pharmaceuticals ETF in Q4 2022 and held it in 6 quarters.
  • Armstrong Advisory Group's iShares US Pharmaceuticals ETF position peaked at $19.4K in Q4 2022.
  • 143 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2024.

Based on Armstrong Advisory Group's 13F filing for Q2 2024, filed 12 Jul 2024.